MOCHIDA PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,205 JPY | +0.47% |
|
+1.26% | -1.99% |
| Apr. 25 | Hidehiro Imatsu named president of Goldman Sachs Japan | RE |
| Mar. 21 | Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. | CI |
ETFs positioned on Mochida Pharmaceutical Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.24% | 15 M€ | +11.00% | ||
| 0.02% | 4 M€ | +16.67% | ||
| 0.02% | 18 M€ | +16.15% | - | |
| 0.01% | 20,721 M€ | +15.36% | - | |
| 0.01% | 144,586 M€ | +16.45% | ||
| 0.01% | 66,066 M€ | +16.60% | - | |
| 0.01% | 7 M€ | +1.36% | - | |
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +1.94% | - |
Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,190
JPY
Average target price
3,200
JPY
Spread / Average Target
+0.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.99% | 719M | |
| +33.41% | 704B | |
| +28.59% | 577B | |
| -3.21% | 348B | |
| +19.01% | 327B | |
| +4.82% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.50% | 147B |
- Stock Market
- Equities
- 4534 Stock
- Funds and ETFs Mochida Pharmaceutical Co., Ltd.
